ESR1 and breast neoplasm: Although ERα-positive breast tumors initially respond to hormonal manipulation, such as tamoxifen, which is an antiestrogen agent, patients with triple-negative breast cancer (TNBC) or ERα-negative breast tumors do not benefit from antihormonal therapy or traditional chemotherapy4–6.